Australia Fertility Services Market Projected to Reach USD 2,889.2 Million by 2034
- Market Research Insights
- Jun 11
- 6 min read
Market Overview
The Australia fertility services market is witnessing strong growth driven by rising demand from delayed parenthood, increased infertility diagnoses, broader awareness, technological advances like genetic screening, and growing adoption of fertility preservation. The market size reached USD 1,038.8 Million in 2025 and is projected to reach USD 2,889.2 Million by 2034, exhibiting a compound annual growth rate (CAGR) of 11.68% during 2026‑2034. These drivers, combined with expanding accessibility and supportive healthcare initiatives, are contributing to Australia fertility services market share.
This market is strategically important to Australia’s healthcare and reproductive medicine economy, supporting individuals and couples in family planning through advanced assisted reproductive technologies. Broader availability of advanced contraceptives, targeted therapies for conditions like endometriosis, and wider use of hormone‑based support for IVF are reshaping patient care pathways. These developments reduce cost barriers, encouraging more individuals to pursue family planning and fertility treatments earlier. With supportive healthcare policies and rising awareness of treatment options, providers are expected to see higher patient volumes.
The Australia fertility services market is poised for sustained expansion, driven by delayed parenthood trends, government funding initiatives, and technological innovations. With a projected CAGR of 11.68% through 2034, the market presents significant opportunities for providers focusing on IVF, genetic screening, and fertility preservation services.
AUSTRALIA FERTILITY SERVICES MARKET SUMMARY
The Australia fertility services market encompasses a range of reproductive health services including in‑vitro fertilisation (IVF), intracytoplasmic sperm injection (ICSI), egg freezing, genetic screening, and fertility preservation, provided across public and private healthcare settings.
The ecosystem spans fertility clinics, hospitals, assisted reproductive technology (ART) laboratories, and government healthcare programs.
Major segments identified in the fertility services industry include cause of infertility (male infertility, female infertility), procedure, service, end user, and region (Australia Capital Territory & New South Wales, Victoria & Tasmania, Queensland, Northern Territory & Southern Australia, Western Australia).
Key trends shaping the market include expanding access to reproductive healthcare, public funding for fertility care, and increasing adoption of genetic screening technologies.
PORTER'S FIVE FORCES ANALYSIS – AUSTRALIA FERTILITY SERVICES MARKET
The competitive dynamics of the Australia fertility services market can be analysed using Porter's Five Forces framework.
Bargaining Power of Suppliers – Moderate
Fertility service providers rely on suppliers of laboratory equipment, cryopreservation materials, culture media, and genetic testing technologies. The technical expertise required for advanced procedures such as genetic screening gives specialised equipment suppliers moderate leverage. However, the presence of multiple global suppliers helps balance supplier influence.
Bargaining Power of Buyers – Moderate to High
Patients seeking fertility treatment benefit from a growing range of clinic options across public and private healthcare settings. The ability to compare success rates, treatment costs, and service offerings strengthens patient negotiating power. Government funding initiatives, including expanded Pharmaceutical Benefits Scheme listings, improve affordability and accessibility.
Threat of New Entrants – Moderate
Significant capital requirements for clinical facilities, laboratory equipment, regulatory approvals, and specialist staffing create barriers. However, the growing demand for fertility preservation and genetic screening has enabled niche clinics and specialised service providers to enter the market with differentiated offerings.
Threat of Substitutes – Low
Adoption and surrogacy represent partial substitutes, but the availability of advanced ART procedures and fertility preservation options provides comprehensive family planning solutions. The increasing acceptance of ART across all demographics continues to drive demand.
Competitive Rivalry – High (Healthy)
The market features intensifying competition among fertility clinics, with providers differentiating through success rates, technology adoption, patient support services, and pricing transparency. In March 2025, the Australian Government expanded Pharmaceutical Benefits Scheme listings to make contraception, endometriosis treatments, and IVF medications more accessible.
Request for Sample Report: https://www.imarcgroup.com/australia-fertility-services-market/requestsample
MARKET GROWTH DRIVERS
Expanding Access to Reproductive Healthcare
The fertility services market in Australia is seeing growth as affordability and access to reproductive treatments improve. Broader availability of advanced contraceptives, targeted therapies for conditions like endometriosis, and wider use of hormone‑based support for IVF are reshaping patient care pathways. These developments reduce cost barriers, encouraging more individuals to pursue family planning and fertility treatments earlier. The market is also benefiting from increased demand for specialized clinics that can deliver comprehensive reproductive care. In March 2025, the Australian Government expanded Pharmaceutical Benefits Scheme listings to make contraception, endometriosis treatments, and IVF medications more accessible. The new listings include Slinda (progestogen‑only contraceptive), Ryeqo (endometriosis), and broader access to Pergoveris (IVF hormone therapy).
Public Support for Fertility Care
Fertility services in Queensland are being reshaped through new public funding that improves access for residents affected by serious illnesses such as cancer. The initiative directs resources toward subsidized assisted reproductive technology within public hospitals, reducing financial strain for patients who often face additional medical costs. Alongside clinical support, counselling services are being integrated to address the emotional and psychological challenges linked to treatment. In March 2024, Queensland's government unveiled a public funding package to expand fertility treatment access for residents who have faced serious illnesses like cancer, allocating funds for subsidized assisted reproductive technology in public hospitals and including counselling services to support those undergoing treatment.
Technological Advances and Fertility Preservation Adoption
Technological advances including genetic screening and fertility preservation are driving market growth. The growing adoption of egg freezing for elective and medical reasons is expanding the patient base for fertility services. Improved success rates from pre‑implantation genetic testing (PGT) are increasing confidence in ART outcomes. As awareness of fertility preservation options grows, more individuals are proactively seeking services to plan their families around career, education, and personal timelines.
AUSTRALIA FERTILITY SERVICES MARKET SEGMENTATION
Segmentation analysis provides a detailed view of the Australia fertility services market by category:
Cause of Infertility Insights: Male Infertility, Female Infertility.
Procedure Insights: In‑Vitro Fertilisation (IVF), Intracytoplasmic Sperm Injection (ICSI), Egg Freezing, Genetic Screening, Others.
Service Insights: Consultation, Treatment, Preservation, Counselling.
End User Insights: Fertility Clinics, Hospitals, Others.
Regional Insights: Australia Capital Territory & New South Wales, Victoria & Tasmania, Queensland, Northern Territory & Southern Australia, Western Australia.
COMPETITIVE LANDSCAPE
The competitive landscape of the Australia fertility services market is dynamic, featuring a mix of public hospital fertility units, private fertility clinics, and specialised ART service providers. The market research report provides a comprehensive analysis of the competitive landscape, including market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant, with detailed profiles of all major companies provided in the full report. Investment opportunities exist in IVF clinic expansion, genetic screening services, fertility preservation technologies, and telehealth fertility consultations.
REGIONAL ANALYSIS
Australia Capital Territory & New South Wales represents a critical demand centre, anchored by Sydney's concentration of fertility clinics, advanced ART laboratories, and strong healthcare infrastructure supporting reproductive medicine.
Victoria & Tasmania benefits from Melbourne's robust healthcare research ecosystem and growing demand for fertility preservation services among professional women.
Queensland sees rising demand driven by state government public funding initiatives for fertility care, particularly for residents affected by serious illnesses such as cancer.
Western Australia experiences steady growth supported by Perth's expanding healthcare network and increasing awareness of fertility preservation options.
Northern Territory & Southern Australia, though smaller in market share, are benefiting from telehealth fertility consultations and improved access to specialised services.
RECENT INDUSTRY DEVELOPMENTS
March 2025: The Australian Government expanded Pharmaceutical Benefits Scheme listings to make contraception, endometriosis treatments, and IVF medications more accessible. The new listings include Slinda (progestogen‑only contraceptive), Ryeqo (endometriosis), and broader access to Pergoveris (IVF hormone therapy).
March 2024: Queensland's government unveiled a public funding package to expand fertility treatment access for residents who have faced serious illnesses like cancer. The initiative allocates funds for subsidized assisted reproductive technology in public hospitals and includes counselling services to support those undergoing treatment.
Note: If you need any specific information that is not covered currently within the scope of the report, we will provide the same as a part of customization.
ABOUT US
IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
CONTACT US
IMARC Group134 N 4th St., Brooklyn, NY 11249, USAEmail: sales@imarcgroup.comTel No: (D) +91 120 433 0800United States: +1 201 971 6302
Comments